Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Breast Cancer

Free Subscription 18.06.2018 1 Am J Clin Oncol 2 Ann Oncol 1 BMC Cancer 2 Br J Cancer 4 Breast Cancer (Auckl) 11 Breast Cancer Res 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 3 Cancer Res 1 Carcinogenesis 5 Clin Breast Cancer 3 Clin Cancer Res 2 Eur J Cancer 1 Eur J Surg Oncol 1 Gene 4 Int J Oncol 1 J Clin Oncol 1 J Nucl Med 2 JAMA 1 Lancet Oncol 2 N Engl J Med 2 Oncol Rep 2 PLoS Comput Biol 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Am J Clin Oncol

1. GEARA FB, Eid T, Zouain N, Thebian R, et al
   Randomized, Prospective, Open-label Phase III Trial Comparing Mebo Ointment With Biafine Cream for the Management of Acute Dermatitis During Radiotherapy for Breast Cancer.
   Am J Clin Oncol. 2018 Jun 7. doi: 10.1097/COC.0000000000000460.
   PubMed     Text format     Abstract available
   
   

   
   Ann Oncol

2. IGNATIADIS M, Litiere S, Rothe F, Riethdorf S, et al
   Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.
   Ann Oncol. 2018 Jun 11. pii: 5035683. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
3. MALORNI L, Curigliano G, Minisini AM, Cinieri S, et al
   Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
   Ann Oncol. 2018 Jun 11. pii: 5035682. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

4. VENTURELLI E, Orenti A, Fabricio ASC, Garrone G, et al
   Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.
   BMC Cancer. 2018;18:651.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

5. CHERIYATH V, Kaur J, Davenport A, Khalel A, et al
   G1P3 (IFI6), a mitochondrial localised antiapoptotic protein, promotes metastatic potential of breast cancer cells through mtROS.
   Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0137.
   PubMed     Text format     Abstract available
   
   
6. GUIU S, Mollevi C, Charon-Barra C, Boissiere F, et al
   Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
   Br J Cancer. 2018 Jun 8. pii: 10.1038/s41416-018-0142.
   PubMed     Text format     Abstract available
   
   

   
   Breast Cancer (Auckl)

7. MAKHOUL I, Atiq M, Alwbari A, Kieber-Emmons T, et al
   Breast Cancer Immunotherapy: An Update.
   Breast Cancer (Auckl). 2018;12:1178223418774802.
   PubMed     Text format     Abstract available
   
   
8. PENG J, Wang W, Hua S, Liu L, et al
   Roles of Extracellular Vesicles in Metastatic Breast Cancer.
   Breast Cancer (Auckl). 2018;12:1178223418767666.
   PubMed     Text format     Abstract available
   
   
9. WEIR J, Zhao YD, Herman T, Algan O, et al
   Clinicopathologic Features and Radiation Therapy Utilization in Patients with Male Breast Cancer: A National Cancer Database Study.
   Breast Cancer (Auckl). 2018;12:1178223418770687.
   PubMed     Text format     Abstract available
   
   
10. TIPPIT D, Siegel E, Ochoa D, Pennisi A, et al
    Upper-Extremity Deep Vein Thrombosis in Patients With Breast Cancer With Chest Versus Arm Central Venous Port Catheters.
    Breast Cancer (Auckl). 2018;12:1178223418771909.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

11. ZHU Q, Tannenbaum S, Kurtzman SH, DeFusco P, et al
    Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Breast Cancer Res. 2018;20:56.
    PubMed     Text format     Abstract available
    
    
12. SEVINSKY CJ, Khan F, Kokabee L, Darehshouri A, et al
    NDRG1 regulates neutral lipid metabolism in breast cancer cells.
    Breast Cancer Res. 2018;20:55.
    PubMed     Text format     Abstract available
    
    
13. JIN K, Pandey NB, Popel AS
    Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Breast Cancer Res. 2018;20:54.
    PubMed     Text format     Abstract available
    
    
14. GILES ED, Jindal S, Wellberg EA, Schedin T, et al
    Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer.
    Breast Cancer Res. 2018;20:50.
    PubMed     Text format     Abstract available
    
    
15. RIBAS R, Pancholi S, Rani A, Schuster E, et al
    Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Breast Cancer Res. 2018;20:44.
    PubMed     Text format     Abstract available
    
    
16. TAWARA K, Bolin C, Koncinsky J, Kadaba S, et al
    OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
    Breast Cancer Res. 2018;20:53.
    PubMed     Text format     Abstract available
    
    
17. WANG C, Brentnall AR, Cuzick J, Harkness EF, et al
    Exploring the prediction performance for breast cancer risk based on volumetric mammographic density at different thresholds.
    Breast Cancer Res. 2018;20:49.
    PubMed     Text format     Abstract available
    
    
18. LARSSON AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, et al
    Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Breast Cancer Res. 2018;20:48.
    PubMed     Text format     Abstract available
    
    
19. PAPANASTASIOU AD, Sirinian C, Kalofonos HP
    Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration.
    Breast Cancer Res. 2018;20:47.
    PubMed     Text format     Abstract available
    
    
20. KRIKKEN E, Khlebnikov V, Zaiss M, Jibodh RA, et al
    Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients.
    Breast Cancer Res. 2018;20:51.
    PubMed     Text format     Abstract available
    
    
21. NORTON N, Fox N, McCarl CA, Tenner KS, et al
    Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
    Breast Cancer Res. 2018;20:52.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Chemother Pharmacol

22. RODON J, Perez-Fidalgo A, Krop IE, Burris H, et al
    Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
    Cancer Chemother Pharmacol. 2018 Jun 7. pii: 10.1007/s00280-018-3610.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

23. SCANNELL BRYAN M, Argos M, Andrulis IL, Hopper JL, et al
    Germline variation and breast cancer incidence: A gene-based association study and whole-genome prediction of early onset breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2018 Jun 13. pii: 1055-9965.EPI-17-1185.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Lett

24. SALINAS-VERA YM, Marchat LA, Garcia-Vazquez R, Gonzalez de la Rosa CH, et al
    Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells.
    Cancer Lett. 2018;432:17-27.
    PubMed     Text format     Abstract available
    
    
25. SAUVAGE F, Fattal E, Al-Shaer W, Denis S, et al
    Antitumor activity of nanoliposomes encapsulating the novobiocin analogue 6BrCaQ in a triple-negative breast cancer model in mice.
    Cancer Lett. 2018 Jun 5. pii: S0304-3835(18)30397.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

26. HE JP, Hou PP, Chen QT, Wang WJ, et al
    Flightless-I blocks p62-mediated recognition of LC3 to impede selective autophagy and promote breast cancer progression.
    Cancer Res. 2018 Jun 13. pii: 0008-5472.CAN-17-3835.
    PubMed     Text format     Abstract available
    
    
27. GOOD CR, Panjarian S, Kelly AD, Madzo J, et al
    TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-2082.
    PubMed     Text format     Abstract available
    
    
28. LU H, Tran L, Park Y, Chen I, et al
    Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF-1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Cancer Res. 2018 Jun 7. pii: 0008-5472.CAN-18-0270.
    PubMed     Text format     Abstract available
    
    

    
    Carcinogenesis

29. MOTA M, Jackson WP, Bailey SK, Vayalil P, et al
    Deficiency of Tumor Suppressor Merlin Facilitates Metabolic Adaptation by co-operative Engagement of SMAD-Hippo Signaling in Breast Cancer.
    Carcinogenesis. 2018 Jun 9. pii: 5035377. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Clin Breast Cancer

30. CADOO KA, Kaufman PA, Seidman AD, Chang C, et al
    Phase 2 Study of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early-Stage Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Clin Breast Cancer. 2018 Apr 7. pii: S1526-8209(17)30768.
    PubMed     Text format     Abstract available
    
    
31. LECLERC AF, Slomian J, Jerusalem G, Coucke P, et al
    Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months' Follow-up.
    Clin Breast Cancer. 2018 May 19. pii: S1526-8209(17)30809.
    PubMed     Text format     Abstract available
    
    
32. JABIR RS, Ho GF, Annuar MABA, Stanslas J, et al
    Association of Allelic Interaction of Single Nucleotide Polymorphisms of Influx and Efflux Transporters Genes With Nonhematologic Adverse Events of Docetaxel in Breast Cancer Patients.
    Clin Breast Cancer. 2018 May 4. pii: S1526-8209(17)30628.
    PubMed     Text format     Abstract available
    
    
33. HU ZY, Xiao H, Xiao M, Tang Y, et al
    Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
    Clin Breast Cancer. 2018 Apr 19. pii: S1526-8209(18)30048.
    PubMed     Text format     Abstract available
    
    
34. RAYSON D, Payne JI, Michael JCR, Tsuruda KM, et al
    Impact of Detection Method and Age on Survival Outcomes in Triple-Negative Breast Cancer: A Population-Based Cohort Analysis.
    Clin Breast Cancer. 2018 Apr 28. pii: S1526-8209(17)30829.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

35. BARRY P, Vatsiou A, Spiteri I, Nichol D, et al
    The spatio-temporal evolution of lymph node spread in early breast cancer.
    Clin Cancer Res. 2018 Jun 11. pii: 1078-0432.CCR-17-3374.
    PubMed     Text format     Abstract available
    
    
36. SHAH D, Wyatt D, Baker A, Simms P, et al
    Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1.
    Clin Cancer Res. 2018 Jun 12. pii: 1078-0432.CCR-17-1952.
    PubMed     Text format     Abstract available
    
    
37. BARDIA A, Hurvitz S
    Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances.
    Clin Cancer Res. 2018 Jun 8. pii: 1078-0432.CCR-18-0162.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

38. GORI S, Puglisi F, Cinquini M, Pappagallo G, et al
    Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Eur J Cancer. 2018;99:9-19.
    PubMed     Text format     Abstract available
    
    
39. DERKS MGM, Bastiaannet E, van de Water W, de Glas NA, et al
    Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
    Eur J Cancer. 2018;99:1-8.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Surg Oncol

40. KARAKATSANIS A, Obondo C, Abdsaleh S, Hersi AF, et al
    Optimisation of breast MRI compatibility after sentinel node biopsy with paramagnetic tracers.
    Eur J Surg Oncol. 2018;44:731-732.
    PubMed     Text format    
    
    

    
    Gene

41. HESARI Z, Nourbakhsh M, Hosseinkhani S, Abdolvahabi Z, et al
    Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
    Gene. 2018 Jun 7. pii: S0378-1119(18)30672-3. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available
    
    

    
    Int J Oncol

42. CHANG LC, Hsieh MT, Yang JS, Lu CC, et al
    Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study.
    Int J Oncol. 2018;52:67-76.
    PubMed     Text format     Abstract available
    
    
43. CARLISLE SM, Hein DW
    Retrospective analysis of estrogen receptor 1 and Nacetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines.
    Int J Oncol. 2018 Jun 11. doi: 10.3892/ijo.2018.4436.
    PubMed     Text format     Abstract available
    
    
44. WANG Y, Yu X, Song H, Feng D, et al
    The STAT-ROS cycle extends IFNinduced cancer cell apoptosis.
    Int J Oncol. 2018;52:305-313.
    PubMed     Text format     Abstract available
    
    
45. NOWAK A, Dziegiel P
    Implications of nestin in breast cancer pathogenesis (Review).
    Int J Oncol. 2018 Jun 14. doi: 10.3892/ijo.2018.4441.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

46. LYMAN GH, Greenlee H, Bohlke K, Bao T, et al
    Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
    J Clin Oncol. 2018 Jun 11:JCO2018792721. doi: 10.1200/JCO.2018.79.2721.
    PubMed     Text format     Abstract available
    
    

    
    J Nucl Med

47. SAH BR, Ghafoor S, Burger IA, Ter Voert EEGW, et al
    Feasibility of (18)F-FDG Dose Reductions in Breast Cancer PET/MRI.
    J Nucl Med. 2018 Jun 7. pii: jnumed.118.209007. doi: 10.2967/jnumed.118.209007.
    PubMed     Text format     Abstract available
    
    

    
    JAMA

48. PLEVRITIS SK, Berry DA, Mandelblatt JS
    Contributions of Screening and Treatment to Mortality From Breast Cancer-Reply.
    JAMA. 2018;319:2336.
    PubMed     Text format    
    
    
49. CHEN HH
    Contributions of Screening and Treatment to Mortality From Breast Cancer.
    JAMA. 2018;319:2335-2336.
    PubMed     Text format    
    
    

    
    Lancet Oncol

50. VON MINCKWITZ G, Colleoni M, Kolberg HC, Morales S, et al
    Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30241.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

51. GIORDANO SH
    Breast Cancer in Men.
    N Engl J Med. 2018;378:2311-2320.
    PubMed     Text format    
    
    
52. MULASI I
    The Scarlet Virus.
    N Engl J Med. 2018;378:2157-2159.
    PubMed     Text format    
    
    

    
    Oncol Rep

53. CANZONERI R, Rabassa ME, Gurruchaga A, Ferretti V, et al
    Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6489.
    PubMed     Text format     Abstract available
    
    
54. ZHAO W, Kuai X, Zhou X, Jia L, et al
    Trop2 is a potential biomarker for the promotion of EMT in human breast cancer.
    Oncol Rep. 2018 Jun 14. doi: 10.3892/or.2018.6496.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Comput Biol

55. GHAFFARIZADEH A, Heiland R, Friedman SH, Mumenthaler SM, et al
    PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems.
    PLoS Comput Biol. 2018;14:e1005991.
    PubMed     Text format     Abstract available
    
    
56. SHIMONI Y
    Association between expression of random gene sets and survival is evident in multiple cancer types and may be explained by sub-classification.
    PLoS Comput Biol. 2018;14:e1006026.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

57. HAN X, Zhao J, Ruddy KJ, Lin CC, et al
    The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women.
    PLoS One. 2018;13:e0198771.
    PubMed     Text format     Abstract available
    
    
58. ASTVATSATURYAN K, Yue Y, Walts AE, Bose S, et al
    Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
    PLoS One. 2018;13:e0197827.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: